A detailed history of Excalibur Management Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Excalibur Management Corp holds 23,943 shares of GILD stock, worth $2.11 Million. This represents 0.67% of its overall portfolio holdings.

Number of Shares
23,943
Previous 22,862 4.73%
Holding current value
$2.11 Million
Previous $1.67 Million 1.91%
% of portfolio
0.67%
Previous 0.71%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$63.15 - $72.88 $68,265 - $78,783
1,081 Added 4.73%
23,943 $1.64 Million
Q1 2024

May 13, 2024

BUY
$71.58 - $87.29 $72,295 - $88,162
1,010 Added 4.62%
22,862 $1.67 Million
Q4 2023

Feb 12, 2024

SELL
$73.27 - $83.09 $20,808 - $23,597
-284 Reduced 1.28%
21,852 $1.77 Million
Q3 2023

Nov 09, 2023

BUY
$73.94 - $80.67 $12,643 - $13,794
171 Added 0.78%
22,136 $1.66 Million
Q2 2023

Aug 08, 2023

SELL
$76.01 - $86.7 $59,287 - $67,626
-780 Reduced 3.43%
21,965 $1.69 Million
Q1 2023

May 05, 2023

SELL
$77.31 - $88.08 $10,436 - $11,890
-135 Reduced 0.59%
22,745 $1.89 Million
Q4 2022

Feb 10, 2023

SELL
$62.32 - $89.47 $57,334 - $82,312
-920 Reduced 3.87%
22,880 $1.96 Million
Q3 2022

Nov 04, 2022

BUY
$59.54 - $68.01 $3,274 - $3,740
55 Added 0.23%
23,800 $1.47 Million
Q2 2022

Jul 25, 2022

BUY
$57.72 - $65.01 $865 - $975
15 Added 0.06%
23,745 $1.47 Million
Q1 2022

May 03, 2022

BUY
$57.92 - $72.58 $226,872 - $284,295
3,917 Added 19.77%
23,730 $1.41 Million
Q4 2021

Feb 10, 2022

BUY
$64.88 - $73.64 $4,282 - $4,860
66 Added 0.33%
19,813 $1.44 Million
Q3 2021

Oct 28, 2021

BUY
$67.69 - $73.03 $23,962 - $25,852
354 Added 1.83%
19,747 $1.38 Million
Q2 2021

Jul 26, 2021

BUY
$63.47 - $69.35 $119,640 - $130,724
1,885 Added 10.77%
19,393 $1.34 Million
Q1 2021

May 03, 2021

SELL
$60.0 - $68.46 $16,020 - $18,278
-267 Reduced 1.5%
17,508 $1.13 Million
Q4 2020

Jan 26, 2021

SELL
$56.65 - $64.55 $8,440 - $9,617
-149 Reduced 0.83%
17,775 $1.04 Million
Q3 2020

Nov 02, 2020

BUY
$62.1 - $78.08 $202,570 - $254,696
3,262 Added 22.25%
17,924 $1.13 Million
Q2 2020

Aug 14, 2020

BUY
$72.34 - $84.0 $221,288 - $256,956
3,059 Added 26.36%
14,662 $1.13 Million
Q1 2020

May 15, 2020

BUY
$62.63 - $80.22 $116,742 - $149,530
1,864 Added 19.14%
11,603 $867,000
Q4 2019

Feb 04, 2020

SELL
$61.62 - $67.78 $204,270 - $224,690
-3,315 Reduced 25.39%
9,739 $633,000
Q3 2019

Oct 21, 2019

BUY
$62.51 - $69.0 $15,189 - $16,767
243 Added 1.9%
13,054 $827,000
Q2 2019

Jul 26, 2019

BUY
$61.87 - $69.38 $17,323 - $19,426
280 Added 2.23%
12,811 $866,000
Q1 2019

Apr 24, 2019

SELL
$62.53 - $70.05 $1,563 - $1,751
-25 Reduced 0.2%
12,531 $815,000
Q4 2018

Jan 29, 2019

SELL
$60.54 - $79.0 $48,432 - $63,200
-800 Reduced 5.99%
12,556 $785,000
Q3 2018

Oct 25, 2018

SELL
$71.28 - $78.92 $18,889 - $20,913
-265 Reduced 1.95%
13,356 $1.03 Million
Q2 2018

Jul 26, 2018

BUY
$64.88 - $75.68 $5,514 - $6,432
85 Added 0.63%
13,621 $965,000
Q1 2018

Apr 23, 2018

SELL
$72.84 - $88.8 $210,361 - $256,454
-2,888 Reduced 17.58%
13,536 $1.02 Million
Q4 2017

Jan 22, 2018

SELL
$71.15 - $83.52 $476,918 - $559,834
-6,703 Reduced 28.98%
16,424 $1.18 Million
Q3 2017

Oct 25, 2017

BUY
$72.11 - $85.47 $1.67 Million - $1.98 Million
23,127
23,127 $1.87 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Excalibur Management Corp Portfolio

Follow Excalibur Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Excalibur Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Excalibur Management Corp with notifications on news.